Loading...
Loading...
GOVX| Name | Value |
|---|---|
| Revenues | 300.7K |
| Cost of Revenue | 23.7K |
| Gross Profit | 276.9K |
| Operating Expense | 5,339.2K |
| Operating I/L | -5,062.2K |
| Other Income/Expense | -1.8K |
| Interest Income | 5.5K |
| Pretax | -5,064.0K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -5,064.0K |
GeoVax Labs, Inc. is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies. It generates revenue through the development and commercialization of preventive vaccines for infectious diseases such as COVID-19, HIV, Zika virus, malaria, and hemorrhagic fever viruses, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company's modified vaccinia ankara virus-like particle vaccine platform serves as the basis for its product portfolio. GeoVax Labs, Inc. has established collaboration and partnership agreements with prominent institutions and organizations, including the National Institutes of Health and the U.S. Department of Defense.
